Improved time in range over 1 year is associated with reduced albuminuria in individuals with sensor-augmented insulin pump-treated type 1 diabetes
The DOI matches its Crossref record; 12 of the 13 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate the association between treatment-induced change in continuous glucose monitoring (CGM) time in range (TIR) and albuminuria in persons with type 1 diabetes (T1D) treated with sensor-augmented insulin pumps (SAP). RESEARCH DESIGN AND METHODS: Twenty-six out of 55 participants with albuminuria and multiple daily injection therapy (25% females; median 51 [interquartile range 46–63] years of age; glycated hemoglobin A1c (HbA1c) 75 [68–88] mmol/mol [9.0% (8.4–10.4%)]; and urinary albumin-to-creatinine ratio (UACR) 89 [37–250] mg/g) were in a randomized controlled trial assigned to SAP therapy for 1 year. Anthropometrics, CGM data, and blood and urine samples were collected every 3 months. RESULTS: Mean change (95% CI) in percentage of TIR (%TIR) was 13.2% (6.2; 20.2), in HbA1c was −14.4 (−17.4; −10.5) mmol/mol (−1.3% [−1.6; −1.0]), and in UACR was −15% (−38; 17) (all P < 0.05). UACR decreased by 19% (10; 28) per 10% increase in %TIR (P = 0.04), 18% (1; 30) per 10 mmol/mol decrease in HbA1c (P = 0.07), and 31% per 10-mmHg decrease in mean arterial pressure (P < 0.001). CONCLUSIONS: In this longitudinal study, treatment-induced increase in %TIR was significantly associated with decrease in albuminuria in T1D.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A 10-to 14-day CGM assessment of TIR, with CGM wear of 70% or higher, and other CGM metrics can be used to assess glycemic status and are useful in clinical management (22)(23)(24)(25)(26).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [24]
In the citing paper
“TIR is associated with microvascular complications (45,46), and a TIR of 70% roughly corresponds to an HbA 1c of 53 mmol/mol (7.0%).”
In the citing paper
“Although the evidence of HbA 1c reduction remains the most robust measure associated with chronic diabetes complications and is the only measure that is prospectively validated, more recent studies have begun to examine the relationship between time that glucose is within the target range and long-term complications and have provided the basis for glycemic targets with newer glucose monitoring”
In the citing paper
“Hypoglycemia with glucose levels below 3.0 mmol/L (54 mg/dL) occurs much more often than previously appreciated (46,101).”
Citations
Cites
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Self-citationInternational consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citationValidation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
Beck, R. W., Bergenstal, R. M., Riddlesworth, T. D., Kollman, C., Li, Z., Brown, A. S., & Close, K. L. (2019) · Diabetes Care · doi:10.2337/dc18-1444 · Cited by 793
Villena Gonzales, W., Mobashsher, A., & Abbosh, A. (2019) · Sensors · doi:10.3390/s19040800 · Cited by 772
The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2016) · Diabetes Care · doi:10.2337/dc15-1990 · Cited by 712
Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring
Bergenstal, R. M., Beck, R. W., Close, K. L., Grunberger, G., Sacks, D. B., Kowalski, A., Brown, A. S., Heinemann, L., Aleppo, G., Ryan, D. B., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1581 · Cited by 684
Mayeda, L., Katz, R., Ahmad, I., Bansal, N., Batacchi, Z., Hirsch, I. B., Robinson, N., Trence, D. L., Zelnick, L., & de Boer, I. H. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000991 · Cited by 162
Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring
Xing, D., Kollman, C., Beck, R. W., Tamborlane, W. V., Laffel, L., Buckingham, B. A., Wilson, D. M., Weinzimer, S., Fiallo-Scharer, R., & Ruedy for the Juvenile Diabetes Research Foundation Continuo, K. J. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0156 · Cited by 131
Yoo, J. H., Choi, M. S., Ahn, J., Park, S. W., Kim, Y., Hur, K. Y., Jin, S.-M., Kim, G., & Kim, J. H. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0499 · Cited by 98
Cited by
6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
“TIR is associated with microvascular complications (45,46), and a TIR of 70% roughly corresponds to an HbA1c of 53 mmol/mol (7.”
Self-citation6. Glycemic Targets: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s006 · Cited by 684
6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s006 · Cited by 486
6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s006 · Cited by 440
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05568-3 · Cited by 378
Self-citationReal-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users
Silva, J. D., Lepore, G., Battelino, T., Arrieta, A., Castañeda, J., Grossman, B., Shin, J., & Cohen, O. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0203 · Cited by 229
“For example, a recent prospective study demonstrated the combined and independent contribution of improved time-in-range (TIR) and HbA1c in reducing microalbuminuria.(3) The MiniMed 670G system (Medtronic, Northridge, CA, USA), the first hybrid closed-loop system approved for use, demonstrated the ability for users to…”
BackgroundVariability of risk factors and diabetes complications
Ceriello, A., & Prattichizzo, F. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01289-4 · Cited by 167
“Many observational [1] and some interventional studies [2], as well as post-hoc analyses of trials such as the “Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation” (ADVANCE), [3] the “Trial Comparing Cardiovascular Safety of Insulin Degludec vs.”
BackgroundGlycaemic management in diabetes: old and new approaches
Ceriello, A., Prattichizzo, F., Phillip, M., Hirsch, I. B., Mathieu, C., & Battelino, T. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00245-x · Cited by 139
6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s006 · Cited by 172
Malahi, A. E., Elsen, M. V., Charleer, S., Dirinck, E. L., Ledeganck, K. J., Keymeulen, B., Crenier, L., Radermecker, R. P., Taes, Y., Vercammen, C., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab688 · Cited by 131
“Data in people with T1D are scarce, but in a small study of 26 persons with T1D with albuminuria who were switched from multiple daily injection therapy to sensor augmented pump therapy improved TIR over 1 year was associated with reduced albuminuria, independent of HbA1c, blood pressure, and BMI (31).”
InfluentialRaj, R., Mishra, R., Jha, N., Joshi, V. R., Correa, R. R., & Kern, P. A. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002573 · Cited by 125
Lingvay, I., Buse, J. B., Franek, E., Hansen, M. V., Koefoed, M. M., Mathieu, C., Pettus, J., Stachlewska, K., & Rosenstock, J. (2021) · Diabetes Care · doi:10.2337/dc20-2878 · Cited by 110
Time in Range from Continuous Glucose Monitoring: A Novel Metric for Glycemic Control
Yoo, J. H., & Kim, J. H. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0257 · Cited by 107
“(2020) [31] 26 Patients with T1DM with SAP Albuminuria HR for albuminuria by TIR; CGM (each 10% increase in TIR): 0.”
BackgroundMethodAleppo, G., Beck, R. W., Bailey, R., Ruedy, K. J., Calhoun, P., Peters, A. L., Pop-Busui, R., Philis-Tsimikas, A., Bao, S., Umpierrez, G., et al. (2021) · Diabetes Care · doi:10.2337/dc21-1304 · Cited by 82
Time in range centered diabetes care
Dovč, K., & Battelino, T. (2021) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.30.1 · Cited by 70
Boscari, F., & Avogaro, A. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09635-3 · Cited by 80
Time-in-range for monitoring glucose control: Is it time for a change?
Bellido, V., Pinés-Corrales, P. J., Villar‐Taibo, R., & Ampudia‐Blasco, F. J. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108917 · Cited by 52
The Association of Time in Range and Diabetic Complications: The Evidence Is Strong
Beck, R. W. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0141 · Cited by 37
Friedman, J. G., Cardona, Z., Szmuilowicz, E. D., & Aleppo, G. (2023) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s374663 · Cited by 60
“There has been an overwhelming amount of data published in recent years demonstrating the impact of CGM on the development of diabetes-related complications such as nephropathy, retinopathy, neuropathy, and cardiovascular events.(32,33) One study demonstrated that improved TIR over 1 year is associated with reduced al…”
BackgroundPAULEY, M. E., Tommerdahl, K. L., Snell‐Bergeon, J. K., & Forlenza, G. P. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01799-x · Cited by 46
Clinical Application of Time in Range and Other Metrics
Aleppo, G. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0093 · Cited by 35
Blood Glucose Level Time Series Forecasting: Nested Deep Ensemble Learning Lag Fusion
Khadem, H., Nemat, H., Elliott, D., & Benaissa, M. (2023) · Bioengineering · doi:10.3390/bioengineering10040487 · Cited by 43
“For example, technological breakthroughs, such as continuous glucose monitoring biosensors [17,18] and insulin pumps [19,20], nowadays, serve myriads of type 1 diabetes patients.”
BackgroundSzmuilowicz, E. D., & Aleppo, G. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2110507 · Cited by 27
Mesa, A., Giménez, M., Pueyo, I., Perea, V., Viñals, C., Blanco, J., Vinagre, I., Serés‐Noriega, T., Boswell, L., Esmatjes, E., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109938 · Cited by 30
Yoo, J. H., Kim, J. Y., & Kim, J. H. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0165 · Cited by 27
“21 Lu et al. showed that a 10% increase in TIR was associated with a 7% decrease in the risk for retinopathy ( P = 0.018) and a 6.4% decrease in the risk for intima-media thickness ( P = 0.042) in people with type 2 diabetes.”
InfluentialKlimontov, V. V., Mavlianova, K. R., Орлов, Н. Б., Semenova, J. F., & Korbut, A. I. (2023) · Biomedicines · doi:10.3390/biomedicines11102843 · Cited by 28
“Accumulating evidence suggests a negative association be-tween time in range (TIR) and microvascular complications in subjects with T1D [14,15].”
BackgroundBeyond A1C: exploring continuous glucose monitoring metrics in managing diabetes
Friedman, J. G., Coyne, K., Aleppo, G., & Szmuilowicz, E. D. (2023) · Endocrine Connections · doi:10.1530/ec-23-0085 · Cited by 22
Beck, R. W., & Bergenstal, R. M. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0090 · Cited by 23
Eliasson, B., Kjölhede, E. A., Salö, S., Nielsen, N. F., & Eeg‐Olofsson, K. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01572-z · Cited by 21
“In a subgroup of a study investigating the relationship between treatment‑induced change in TIR and albuminuria in subjects with type 1 diabetes treated with sensor‑augmented insulin pumps (SAPs), a beneficial effect was noted [18].”
BackgroundGavin, J. R., & Bailey, C. J. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0057 · Cited by 18
“Other studies showed similar relationships between %TIR and other diabetes complications, including carotid intimal-media thickening, 41 diabetic neuropathy, 42,43 retinopathy, 44,45 nephropathy, 42,46,47 and CAN, 40,48 a risk factor for increased mortality.”
Protection of diabetes in aortic abdominal aneurysm: Are antidiabetics the real effectors?
Picatoste, B., Cerro-Pardo, I., Blanco‐Colio, L. M., & Martín-Ventura, J. L. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1112430 · Cited by 18
Préau, Y., Galie, S., Schaepelynck, P., Armand, M., & Raccah, D. (2021) · Sensors · doi:10.3390/s21186131 · Cited by 20
Feng, Z., Guo, Q., Wang, W., Yuan, Y., Jin, X., Zhou, H., Liu, J., Lei, H., Yang, X., Liu, J., et al. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00739-z · Cited by 17
Billion, L., Charleer, S., Verbraeken, L., Sterckx, M., Vangelabbeek, K., Block, N. D., Janssen, C., Dessel, K. V., Dirinck, E. L., PEIFFER, F. W., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14527 · Cited by 15
Helleputte, S., Calders, P., Rodenbach, A., Marlier, J., Verroken, C., Backer, T. L. M. D., & Lapauw, B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01717-z · Cited by 13
“next to HbA1c) in predicting diabetic complications, and has been associated with microvascular complication risk in both T1D [12, 13] and type 2 diabetes (T2D) [14].”
BackgroundDifferential correlation between time in range and eGFR or albuminuria in type 2 diabetes
Jin, X., Yang, X., Xu, Y., Liang, J., Liu, C., Guo, Q., Wang, W., Feng, Z., Yuan, Y., Zhou, H., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01071-4 · Cited by 15
“MAGE mean glucose fluctuation amplitude CV coefficient of variation MODD mean absolute difference of daytime glucose ADDR mean daily risk range TBR time below range TAR time above range OR odds ratio CI confidence interval T1DM type 1 diabetes mellitus Authors’ contributions Ping Gu conceived and designed the research.”
BackgroundInfluentialCutruzzolà, A., Parise, M., Scavelli, F. B., Barone, M., Gnasso, A., & Irace, C. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296821993178 · Cited by 13
Wei, Y., Liu, C., Liu, Y., Zhang, Z., Feng, Z., Yang, X., Liu, J., Lei, H., Zhou, H., Shen, Q., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01718-y · Cited by 12
Muthukumar, A., Badawy, L., Mangelis, A., Vas, P. R. J., Thomas, S., Gouber, A., Ayis, S. A., & Karalliedde, J. J. (2024) · Diabetologia · doi:10.1007/s00125-024-06197-2 · Cited by 13
“In contrast, glycaemic optimisation using sensor-augmented insulin pump therapy and continuous glucose monitoring (CGM) systems reduced glycaemic variability and improved time in range, which was associated with a reduction in albuminuria in people with type 1 diabetes and DKD [15].”
BackgroundHallström, S., Hirsch, I. B., Ekelund, M., Sofizadeh, S., Albrektsson, H., Dahlqvist, S., Svensson, J., & Lind, M. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0577 · Cited by 9
Quirós, C., Alonso-Carril, N., Rodriguez-Rodríguez, S., Barahona, M. J., Orois, A., Simó-Servat, A., Ramos, M., & Perea, V. (2022) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2022.10.003 · Cited by 8
Quirós, C., Alonso-Carril, N., Rodriguez-Rodríguez, S., Barahona, M. J., Orois, A., Simó-Servat, A., Ramos, M., & Perea, V. (2023) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2022.10.005 · Cited by 11
Deshmukh, H., Wilmot, E. G., Pieri, B. A., Choudhary, P., Shah, N. Z., Gregory, R., Kilvert, A., Lumb, A. N., Christian, P., Barnes, D., et al. (2022) · Diabetic Medicine · doi:10.1111/dme.14942 · Cited by 8
“10 All the participants in the audit were prescribed the isCGM (16,427).”
BackgroundOhno, T., Tsujino, D., & Nishimura, R. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2400487 · Cited by 6
“Subsequent studies involving individuals with type 1 diabetes (T1D) have reported significant associations between TIR and the presence of diabetes complications [2–5].”
Glycemia Risk Index is Associated With Risk of Albuminuria Among Individuals With Type 1 Diabetes
Kim, J. Y., Yoo, J. H., Kim, N. H., & Kim, J. H. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241310850 · Cited by 5
Peralta, F. G., Gea, I. L., Duque, N., Artime, E., & Santos, M. R. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02943-5 · Cited by 8
Barkai, L., Rácz, O., Eigner, G., & Kovács, L. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01749-x · Cited by 4
“…is an excellent way to assess metabolic control and predict complications, however, according to the data of the Diabetes Control and Complications Trial, blood glucose fluctuations that can be determined in this way do not play a significant role in the development of complications [13, 14].”
Aleppo, G., Bode, B. W., & Carlson, A. L. (2022) · Clinical Diabetes · doi:10.2337/cd21-0056 · Cited by 3
Variation of glucose time in range in type 1 diabetes
Hansen, K. W., & Bibby, B. M. (2022) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.379 · Cited by 2
Rossing, P. R., & Flyvbjerg, A. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch44 · Cited by 3
Self-citationGeoreli, E., Sotiriou, G., Chainoglou, A., Galli‐Τsinopoulou, A., Stabouli, S., & Christoforidis, A. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113132 · Cited by 2
Masuda, T., Katakami, N., Taya, N., Miyashita, K., Takahara, M., Kato, K., Kuroda, A., Matsuhisa, M., & Shimomura, I. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13819 · Cited by 3
Yuan, Y., Lü, B., Guo, Q., Wang, W., Feng, Z., Jin, X., Zhou, H., Liu, J., Lei, H., Yang, X., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109179 · Cited by 3
Girsh, Y. V., Kiyaev, A. V., Slovak, M. A., Korneva, I. V., Промин, И. А., Yusupova, N. A., & Savelyev, L. I. (2022) · Diabetes Mellitus · doi:10.14341/dm12838 · Cited by 2
Automated Insulin Delivery Beyond Glycemic Outcomes: Endpoints and Evidence
Jones, H. C., Trawley, S. L., Jenkins, A. J., MacIsaac, R. J., Kong, Y. W., Morrison, D., & O'Neal, D. N. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251390831 · Cited by 3
“37 CGM use has also been shown to help with improvements in glycemic control in patients with progressive diabetic kidney disease (DKD).”
Masuda, T., Katakami, N., Taya, N., Miyashita, K., Takahara, M., Kato, K., & Shimomura, I. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag224
Grassi, B. A., Caramés, B., Plaza‐Plaza, J. C., Onetto, M. T., Moreno, S., Sandoval, T., Tapia, N., Salas, F. M., & Revello, A. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108262 · Cited by 1
Diabetic Kidney Disease: Identification, Prevention, and Treatment
Caramori, M. L., & Rossing, P. R. (2022) · Springer eBooks · doi:10.1007/978-3-030-98927-9_7 · Cited by 1
Self-citationDiabetic Nephropathy in Type 1 Diabetes Mellitus
Rossing, P. R. (2022) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_15 · Cited by 1
Self-citationBrøsen, J. M. B., Agesen, R. M., Alibegovic, A. C., Andersen, H. U., Beck‐Nielsen, H., Gustenhoff, P., Hansen, T. K., Hedetoft, C., Jensen, T. J., Juhl, C. B., et al. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231197423 · Cited by 1
Self-citationPositioning “Time-in-Range” in the Treatment of Diabetes in India
Mohan, V., Unnikrishnan, A. G., Kesavadev, J., & Saboo, B. (2022) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_2_22
Walicka, M., & Franek, E. (2024) · Clinical Diabetology · doi:10.5603/cd.101353 · Cited by 1
Suganuma, Y., Ishiguro, M., Ohno, T., & Nishimura, R. (2024) · Diabetology International · doi:10.1007/s13340-024-00743-4
“Considering this and the correlation between the improvement in TIR and the decrease in UACR [28], it may be possible that the higher the baseline UACR, the greater the ΔTIR.”
(2022) · American Diabetes Association eBooks · doi:10.2337/9781580407700.ch04
Andreassen, J., Nikontovic, A., Iversen, E. M., Borðoy, R. Á. F., Rasmussen, P., Petersen, M. S., & Johannesen, H. L. (2025) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.05.005
“13,40 Additionally, IPT users showed a greater percentage of normal ACR values, whereas MDI users displayed increased albuminuria.”
InfluentialHe, L., Chen, J., Chen, W., & Shen, X. (2025) · Journal of Laboratory Medicine · doi:10.1515/labmed-2025-0017
“In patients with type 1 diabetes mellitus, 1-year improvement in TIR is associated with reduced proteinuria (a 10 % increase in TIR is associated with a 19 % decrease in UACR) [35].”
Glycemic management in adults with type 1 diabetes
Koliaki, C. C., & Liatis, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00317-4
Association Between Longitudinal Time in Range and Albuminuria in Insulin-Treated Diabetes
Yoshimura, K., Miyazaki, Y., Kobayashi, M., Nakatsuji, M., Saito, S., Nishikage, S., Yamamoto, A., Takayoshi, T., Asahara, S., Ogawa, W., et al. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261462229
“23 However, the previous study had a relatively short follow-up period, focused on changes after the introduction of sensor-augmented pump therapy, and included only individuals who already had albuminuria.”
Time in Range and Adverse Outcomes in Type 2 Diabetes: A Quantitative Synthesis
Qu, F., Yang, Q., Zeng, Q., Li, Z., & Li, J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15145713
“Several cohort studies have suggested that TIR may be more strongly associated with certain adverse outcomes than HbA1c [12–14].”
Continuous Glucose Monitoring and Long-Term Glycemic and Kidney Outcomes
Karter, A. J., Parker, M. M., Finertie, H., Nugent, J. R., Gilliam, L. K., & Mahapatra, A. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.37698
Continuous Glucose Monitoring Glucometrics and Their Role in Predicting Diabetes Complications
Schweiger, D. Š., Mozzillo, E., & Battelino, T. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.08.019
Metadata
- Authors
- Ranjan, A. G., Rosenlund, S. V., Hansen, T. W., Rossing, P., Andersen, S., & Nørgaard, K.
- Affiliations
- Danish Diabetes Academy (DK)
- Steno Diabetes Center Copenhagen (DK)
- University of Copenhagen (DK)
- Corresponding author
- Ranjan, Ajenthen G.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-09-04
- Volume
- 43
- Issue
- 11
- Pages
- 2882-2885
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W3083350156
- Cited by
- 72
- References
- 13
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 8 · 2023: 13 · 2022: 17 · 2021: 20 · 2020: 1
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Danish Diabetes Academy (PD002-19)
- Danish Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- time in range, albuminuria, type 1 diabetes, sensor-augmented insulin pump therapy, continuous glucose monitoring, albumin-creatinine ratio, HbA1c, mean arterial pressure, glycemic control, diabetic nephropathy
- MeSH terms
- Serum Albumin, Human, Albuminuria, Blood Glucose, Creatinine, Diabetes Mellitus, Type 1, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Longitudinal Studies, Male, Middle Aged, Time Factors, Blood Glucose Self-Monitoring, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.